Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Tumors in Adolescent and Young Adult Patients: Not Just Little Adults
Schwartz, Jonathan , Schwartz, Jonathan David

Mayo Clinic

JCO Oncology Practice | April 10, 2020 | Volume: 16 | Issue: 4 | Pages: 163-164

10.1200/jop.20.00012 | PMID 32275850 Get It

18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies
Graff‐Radford, Jonathan , Lesnick, Timothy G. , Savica, Rodolfo , Chen, Qin , Ferman, Tanis J. , Przybelski, Scott A. , Gunter, Jeffrey L. , Kremers, Walter K. , Jack, Clifford R. , Lowe, Val J. , Petersen, Ronald C. , Murray, Melissa E. , Kantarci, Kejal , Dickson, Dennis W , Jack, Clifford R , Kantarci, Kejal , Murray, Melissa E , Ferman, Tanis J , Kremers, Walter K , Jones, David T. , Senjem, Matthew L. , Knopman, David S. , Boeve, Bradley F. , Dickson, Dennis W.

Mayo Clinic

Brain Communications | April 8, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaa040 | PMID 32566926 Get It

AbstractAmong individuals with dementia with Lewy bodies, pathologic correlates of clinical course include the presence and extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease. The objectives of this study are to determine (i) whether 18F-fluorodeoxyglucose PET signature patterns of dementia with Lewy bodies are associated with the extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease and (ii) whether these 18F-fluorodeoxyglucose pattern(s) are associated with clinical course in dementia with Lewy bodies. Two groups of participants were included: a pathology-confirmed subset with Lewy body disease (n = 34) and a clinically diagnosed group of dementia with Lewy bodies (n = 87). A subset of the clinically diagnosed group was followed longitudinally (n = 51). We evaluated whether 18F-fluorodeoxyglucose PET features of dementia with Lewy bodies (higher cingulate island sign ratio and greater occipital hypometabolism) varied by Lewy body disease subtype (transitional versus diffuse) and Braak neurofibrillary tangle stage. We investigated whether the PET features were associated with the clinical trajectories by performing regression models predicting Clinical Dementia Rating Scale Sum of Boxes. Among autopsied participants, there was no difference in cingulate island sign or occipital hypometabolism by Lewy body disease type, but those with a lower Braak tangle stage had a higher cingulate island sign ratio compared to those with a higher Braak tangle stage. Among the clinically diagnosed dementia with Lewy bodies participants, a higher cingulate island ratio was associated with better cognitive scores at baseline and longitudinally. A higher 18F-fluorodeoxyglucose PET cingulate island sign ratio was associated with lower Braak tangle stage at autopsy, predicted a better clinical trajectory in dementia with Lewy body patients and may allow for improved prognostication of the clinical course in this disease.
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
McGovern, Barbara , Ford, Christopher B. , Henn, Matthew R. , Pardi, Darrell S. , Khanna, Sahil , Hohmann, Elizabeth , O’Brien, Edward J., Desjardins, Christopher A. , Bernardo, Patricia, Wortman, Jennifer R. , Lombardo, Mary-Jane, Litcofsky, Kevin , Winkler, Jonathan, McChalicher, Christopher , Li, Sunny S., Tomlinson, Amelia D., Nandakumar, Madhumitha , Cook, David N. , Pomerantz, Roger J., Trucksis, Michele, McGovern, Barbara H , Litcofsky, Kevin D , Wortman, Jennifer , Aunins, John G

Mayo Clinic

Clinical Infectious Diseases | April 5, 2020 | Volume: 72 | Issue: 12 | Pages: 2132-2140

10.1093/cid/ciaa387 | PMID 32255488 Get It

Abstract Background Recurrent Clostridioides difficile infection (rCDI) is associated with loss of microbial diversity and microbe-derived secondary bile acids, which inhibit C. difficile germination and growth. SER-109, an investigational microbiome drug of donor-derived, purified spores, reduced recurrence in a dose-ranging, phase (P) 1 study in subjects with multiple rCDIs. Methods In a P2 double-blind trial, subjects with clinical resolution on standard-of-care antibiotics were stratified by age (< or ≥65 years) and randomized 2:1 to single-dose SER-109 or placebo. Subjects were diagnosed at study entry by PCR or toxin testing. Safety, C. difficile–positive diarrhea through week 8, SER-109 engraftment, and bile acid changes were assessed. Results 89 subjects enrolled (67% female; 80.9% diagnosed by PCR). rCDI rates were lower in the SER-109 arm than placebo (44.1% vs 53.3%) but did not meet statistical significance. In a preplanned analysis, rates were reduced among subjects ≥65 years (45.2% vs 80%, respectively; RR, 1.77; 95% CI, 1.11–2.81), while the <65 group showed no benefit. Early engraftment of SER-109 was associated with nonrecurrence (P < .05) and increased secondary bile acid concentrations (P < .0001). Whole-metagenomic sequencing from this study and the P1 study revealed previously unappreciated dose-dependent engraftment kinetics and confirmed an association between early engraftment and nonrecurrence. Engraftment kinetics suggest that P2 dosing was suboptimal. Adverse events were generally mild to moderate in severity. Conclusions Early SER-109 engraftment was associated with reduced CDI recurrence and favorable safety was observed. A higher dose of SER-109 and requirements for toxin testing were implemented in the current P3 trial. Clinical Trials Registration NCT02437487, https://clinicaltrials.gov/ct2/show/NCT02437487?term=SER-109&draw= 2&rank=4.
Artificial Intelligence and Robotics in Spine Surgery
Shao, Jianning, Neifert, Sean N. , Gibbs, Wende N. , Habboub, Ghaith , Steinmetz, Michael P. , Benzel, Edward, Mroz, Thomas E. , Rasouli, Jonathan J

Mayo Clinic

Global Spine Journal | April 1, 2020 | Volume: 11 | Issue: 4 | Pages: 556-564

10.1177/2192568220915718 | PMID 32875928 Get It

Study Design: Narrative review. Objectives: Artificial intelligence (AI) and machine learning (ML) have emerged as disruptive technologies with the potential to drastically affect clinical decision making in spine surgery. AI can enhance the delivery of spine care in several arenas: (1) preoperative patient workup, patient selection, and outcome prediction; (2) quality and reproducibility of spine research; (3) perioperative surgical assistance and data tracking optimization; and (4) intraoperative surgical performance. The purpose of this narrative review is to concisely assemble, analyze, and discuss current trends and applications of AI and ML in conventional and robotic-assisted spine surgery. Methods: We conducted a comprehensive PubMed search of peer-reviewed articles that were published between 2006 and 2019 examining AI, ML, and robotics in spine surgery. Key findings were then compiled and summarized in this review. Results: The majority of the published AI literature in spine surgery has focused on predictive analytics and supervised image recognition for radiographic diagnosis. Several investigators have studied the use of AI/ML in the perioperative setting in small patient cohorts; pivotal trials are still pending. Conclusions: Artificial intelligence has tremendous potential in revolutionizing comprehensive spine care. Evidence-based, predictive analytics can help surgeons improve preoperative patient selection, surgical indications, and individualized postoperative care. Robotic-assisted surgery, while still in early stages of development, has the potential to reduce surgeon fatigue and improve technical precision.
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial
Schöder, Heiko , Polley, Mei‐Yin C. , Knopp, Michael V. , Kostakoglu, Lale , Zhang, Jun , Higley, Howard R., Kelloff, Gary J. , Liu, Heshan , Zelenetz, Andrew D. , Cheson, Bruce D. , Wagner‐Johnston, Nina D. , Friedberg, Jonathan W. , Leonard, John P. , Schwartz, Lawrence H., Wilson, Wyndham H. , Bartlett, Nancy L. , Bartlett, Nancy L , Kostakoglu, Lale , Zelenetz, Andrew D , Schöder, Heiko , Hall, Nathan C. , Kahl, Brad S. , Hsi, Eric D.

Mayo Clinic

Blood | March 31, 2020 | Volume: 135 | Issue: 25 | Pages: 2224-2234

10.1182/blood.2019003277 | PMID 32232481 Get It

Abstract As part of a randomized, prospective clinical trial in large cell lymphoma, we conducted serial fluorodeoxyglucose positron emission tomography (FDG-PET) at baseline, after 2 cycles of chemotherapy (interim PET [i-PET]), and at end of treatment (EoT) to identify biomarkers of response that are predictive of remission and survival. Scans were interpreted in a core laboratory by 2 imaging experts, using the visual Deauville 5-point scale (5-PS), and by calculating percent change in FDG uptake (change in standardized uptake value [ΔSUV]). Visual scores of 1 through 3 and ΔSUV ≥66% were prospectively defined as negative. Of 524 patients enrolled in the parent trial, 169 agreed to enroll in the PET substudy and 158 were eligible for final analysis. In this selected population, all had FDG-avid disease at baseline; by 5-PS, 55 (35%) remained positive on i-PET and 28 (18%) on EoT PET. Median ΔSUV on i-PET was 86.2%. With a median follow-up of 5 years, ΔSUV, as continuous variable, was associated with progression-free survival (PFS) (hazard ratio [HR] = 0.99; 95% confidence interval [CI], 0.97-1.00; P = .02) and overall survival (OS) (HR, 0.98; 95% CI, 0.97-0.99; P = .03). ΔSUV ≥66% was predictive of OS (HR, 0.31; 95% CI, 0.11-0.85; P = .02) but not PFS (HR, 0.47; 95% CI, 0.19-1.13; P = .09). Visual 5-PS on i-PET did not predict outcome. ΔSUV, but not visual analysis, on i-PET predicted OS in DLBCL, although the low number of events limited the statistical analysis. These data may help guide future clinical trials using PET response-adapted therapy. This trial was registered at www.clinicaltrials.gov as #NCT00118209.
Abstract B15: Therapeutic potential of targeting amino acid metabolism in pancreatic cancer
Fernández-Zapico, Martín E. , Philip, Philip, Vandell, Alexander G., Eckard, Jonathan, Korn, Ron, Priore, Giuseppe Del, Kim, Dae Won , Simeone, Diane M.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 79 | Issue: 24_Supplement | Pages: B15-B15

10.1158/1538-7445.panca19-b15 Get It

Abstract Background: A wide range of cancers, including pancreatic cancer, display altered expression of amino acid transporter LAT-1. LAT-1 overexpression has been shown to be an important prognostic factor and predicts chemo resistance in pancreatic cancer (Kaira K, 2012; Altan B, 2018). Radiolabeled amino acids for PET imaging, including 3-18F-l-α-methyl-tyrosine ([18F] FAMT), have successfully leveraged cancer’s aberrant LAT1 expression and amino acid uptake for decades. SM-88 is a denatured D/L racemic form of α-methyl-tyrosine designed for selective uptake and disruption of protein synthesis in cancer cells, as well as disruption of catecholamine production via inhibition of tyrosine hydroxylase. Catecholamines have been reported to potentially have a role in driving pancreatic cancer progression and changes in the tumor immune status (Renz B, Cancer Cell 2018; Calvani M, Oncotarget 2014). Initial clinical and preclinical results with SM-88 indicate that this agent could pose a novel approach in the treatment of pancreatic cancer. Methods and Results: Initial xenograft models of human gastrointestinal cancers using monotherapy SM-88 showed a >50% decrease in tumor growth at three weeks of treatment (p<0.05). Ongoing preclinical experiments are testing the full pharmacodynamic effects of SM-88 on pancreatic cancer cells, as well as potential effects on the tumor microenvironment due to catecholamine interruption. In results from the ongoing phase 2 trial of SM-88 in heavily pretreated metastatic pancreatic cancer patients, SM-88 has shown monotherapy antitumor activity based on RECIST 1.1 criteria. Additionally, 16/24 patients demonstrated a reduction in circulating tumor cells, with the median nadir decline of 63%. LAT1 has been reported to be important in EMT transition and mesenchymal cell survival (Holldorsson S, Cancer letters 2017); examination of the impact of SM-88 on this important emerging biomarker is ongoing. Conclusion: Altered amino acid (LAT1) metabolism has been shown to be a negative prognosticator in pancreatic cancer outcomes and progression. Targeting LAT1 and amino acid pathways has been identified as a therapeutic approach in multiple cancers (Fuchs BC, Semin Ca Biol 2005). Initial and ongoing studies of SM-88 may clarify the potential utility of this approach in the treatment of pancreatic cancer. Citation Format: Martin Fernandez-Zapico, Dae Won Kim, Philip Philip, Alexander Vandell, Jonathan Eckard, Ron Korn, Giuseppe Del Priore, Diane Simeone. Therapeutic potential of targeting amino acid metabolism in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr B15.
Association of Strabismus With Functional Vision and Eye-Related Quality of Life in Children
Leske, David A. , Castañeda, Yolanda S., Wernimont, Suzanne M., Liebermann, Laura, Cheng-Patel, Christina S., Holmes, Jonathan M. , Hatt, Sarah R. , Birch, Eileen E. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | March 26, 2020 | Volume: 138 | Issue: 5 | Pages: 528

10.1001/jamaophthalmol.2020.0539 | PMID 32215586 Get It

Impact of long-term epidural electrical stimulation enabled task-specific training on secondary conditions of chronic paraplegia in two humans
Veith, Daniel D. , Linde, Margaux , Gill, Megan L., Calvert, Jonathan S. , Grahn, Peter J. , Garlanger, Kristin, Husmann, Douglas A. , Lavrov, Igor , Sayenko, Dimitry G. , Strommen, Jeffrey A., Lee, Kendall, Zhao, Kristin D. , Beck, Lisa, Veith, Daniel, Gill, Megan, Calvert, Jonathan, Grahn, Peter, Husmann, Douglas , Strommen, Jeffrey, Zhao, Kristin, Lavrov, Igor , Trentadue, Taylor P , Sayenko, Dimitry G , Beck, Lisa, Lee, Kendall H.

Mayo Clinic

The Journal of Spinal Cord Medicine | March 23, 2020 | Volume: 44 | Issue: 5 | Pages: 800-805

10.1080/10790268.2020.1739894 | PMID 32202485 Get It

Three‐year observation of children 12 to 35 months old with untreated intermittent exotropia
Cotter, Susan A. , Chandler, Danielle L. , Holmes, Jonathan M. , Wallace, David K. , Melia, B. Michele, Wu, Rui , Kraker, Raymond T. , Superstein, Rosanne , Crouch, Eric R. , Paysse, Evelyn A. , Group, the Pediatric Eye Disease Investigator, Melia, B. Michele, Group, the Pediatric Eye Disease Investigator, Holmes, Jonathan M.

Mayo Clinic

Ophthalmic and Physiological Optics | March 23, 2020 | Volume: 40 | Issue: 2 | Pages: 202-215

10.1111/opo.12668 | PMID 32202318 Get It

Abstract Purpose To describe the clinical course of untreated intermittent exotropia (IXT) in children 12–35 months of age followed for 3 years. Methods We enrolled 97 children 12–35 months of age with previously untreated IXT who had been randomly assigned to the observation arm of a randomised trial of short‐term occlusion versus observation. Participants were observed unless deterioration criteria were met at a follow‐up visit occurring at 3 months, 6 months, and 6‐month intervals thereafter for 3 years. The primary outcome was deterioration of the IXT by 3 years, defined as (1) a constant exotropia ≥10 prism dioptres (∆) at distance and near (i.e., motor deterioration) or (2) treatment prescribed despite not having met motor deterioration. The primary analysis used the Kaplan‐Meier method to determine the cumulative proportion of participants meeting deterioration by three years and 95% confidence interval (CI). Results The cumulative probability of deterioration by 3 years was 28% (95% CI = 20%–39%). Of the 24 participants meeting the primary outcome of deterioration, seven met motor deterioration and 17 were prescribed treatment without meeting motor deterioration. The cumulative probability of motor deterioration by 3 years was 10% (95% CI = 5%–19%). Conclusions Given the modest rate of motor deterioration over three years, watchful waiting may be a reasonable management approach in 12‐ to 35‐month‐old children with IXT. To confirm this recommendation would require a long‐term randomised trial of immediate treatment versus observation followed by deferred treatment if needed.